

ASX Release

Quarterly Cash Flow Report and Trading Update

Quarter ended 30 September 2017

Melbourne, Australia; 31 October 2017: Jayex Healthcare Limited (ASX: JHL) (**Jayex** or **Company**), a leading e-health provider of integrated healthcare services delivery platforms, today released its Appendix 4C – Quarterly cash flow report for the quarter ended 30 September 2017 (the **Quarter**).

During the Quarter JHL's consolidated cash receipts amounted to approximately AUD\$1.689m. Receipts derived from the UK represented approximately 81% of consolidated cash receipts.

Cash at bank over the quarter moved from \$2.051m to \$1.124m.

Operationally the Company continues to deploy its technologies of Appointuit (patient engagement) and the Enlighten Patient Flow Management Platform (patient arrival registration via kiosks, calling screens and wayfinding technologies) across the UK, Australia and New Zealand.

During the quarter the Company's UK operations were behind budget and are slightly behind budget for the year to date. The UK operation recorded invoiced revenue of approximately £707K for the quarter and £3.1M for the year to date (approximately A\$1.18m for the quarter and \$A5.16m year to date).

Contacts for further information:

Chief Executive Officer Nick Fernando 1300 330 611 n.fernando@jayex.com Company Secretary Melanie Leydin 0417 663 119

About Jayex Healthcare Limited - www.jayexhealthcare.com.au

Jayex Healthcare is a leading provider in the United Kingdom and Australia of integrated healthcare services delivery platforms, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Enlighten* patient workflow platform;
- the Appointuit patient engagement solution;
- the *Pharmacy Delivery 2 U* prescription delivery service; and
- the *BluePoint*[®] remote pharmacy prescription processing and dispensing terminal.

+Rule 4.7B

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

JAYEX HEALTHCARE LIMITED

ABN

15 119 122 477

Quarter ended ("current quarter")

30 SEPTEMBER 2017

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	1,689	6,988
1.2	Payments for		
	(a) research and development	(33)	(157)
	 (b) product manufacturing and operating costs 	(792)	(2,158)
	(c) advertising and marketing	(45)	(245)
	(d) leased assets	(92)	(277)
	(e) staff costs	(980)	(3,216)
	(f) administration and corporate costs	(616)	(2,445)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	-
1.5	Interest and other costs of finance paid	(22)	(54)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	(891)	(1,564)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
2.	Cash flows from investing activities		
2.1	Payments to acquire:		
	(a) property, plant and equipment	(1)	(19)
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(1)	(19)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of shares	-	-
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	-	-
3.5	Proceeds from borrowings	-	2,070
3.6	Repayment of borrowings	-	(670)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	-	1,400

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	2,051	1,334
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(891)	(1,564)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(1)	(19)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	1,400
4.5	Effect of movement in exchange rates on cash held	(35)	(27)
4.6	Cash and cash equivalents at end of quarter	1,124	1,124

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,124	2,051
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,124	2,051

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Directors fees, loan interest and premises lease payments for the quarter.

+ See chapter 19 for defined terms	

1 September 2016

Current quarter \$A'000	
(63)	
-	
	1

7.Payments to related entities of the entity and their
associatesCurrent quarter
\$A'0007.1Aggregate amount of payments to these parties included in item 1.2-7.2Aggregate amount of cash flow from loans to these parties included
in item 2.3-7.3Include below any explanation necessary to understand the transactions included in
items 7.1 and 7.2-

Nil

- 8. Financing facilities available Add notes as necessary for an understanding of the position
- 8.1 Loan facilities
- 8.2 Credit standby arrangements
- 8.3 Other (please specify)

Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
2,000	2,000
-	-
-	-

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

Facility amount	Lender	Interest rate	Secured/unsecured
\$2,000,000	Covenant Holdings (WA) Pty Ltd	8.0% per annum	Unsecured
\$250,000	Covenant Holdings (WA) Pty Ltd	12.0% per annum	Unsecured

9.	Estimated cash outflows for next quarter**	\$A'000
9.1	Research and development	73
9.2	Product manufacturing and operating costs	386
9.3	Advertising and marketing	15
9.4	Leases	126
9.5	Staff costs	1,044
9.6	Administration and corporate costs	566
9.7	Other (provide details if material)	-
9.8	Total estimated cash outflows	2,210

* * Please note that the above estimated cash outflows for the next quarter do not include inflows of receipts from customers. The cash outflows are estimates only and variable outflows are calculated on forecast revenue for the quarter. Variable outflows will change if actual revenue differs from forecast revenue.

10.	Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1	Name of entity		
10.2	registration		
10.3			
10.4	Total net assets		
10.5	Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:

..... (Company secretary)

Date: 31 October 2017

Print name: Melanie Leydin

Notes

- 1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- 2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- Dividends received may be classified either as cash flows from operating activities or cash flows 3. from investing activities, depending on the accounting policy of the entity.